Friday 6 November 2026 Export KYMR’s income statement to Excel — free account

Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024.

Revenue: +466.4%
EPS: −40.3%
Free cash flow: −186.6%
Total debt: −66.6%

Quarter to September 2026, against a year earlier

Insider buying

132.01 3.89 +3.04%

Follow KYMR

Alert me

Market cap: $10.9B
P/E: 0.0×
Fwd P/E: −31.6×
Dividend yield: —
F-score: 4/9
Altman Z: 23.22
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Valuation Filings

Kymera Therapeutics, Inc. (KYMR) P/S ratio

Alert me on P/S ratio

As of 6 November 2026, Kymera Therapeutics, Inc. (KYMR) trades at a P/S ratio of 126×. Over the past ten years it has ranged from 0.0× (September 2020) to 221× (June 2026); the current reading is higher than 90% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/KYMR/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Kymera Therapeutics, Inc. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/KYMR/metrics/ps-ratio">Kymera Therapeutics, Inc. (KYMR) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	168×	161.42%
FY2024	64.1×	240.68%
FY2023	18.8×	(34.20%)
FY2022	28.6×	(31.61%)
FY2021	41.8×	32.36%
FY2020	31.6×	—
FY2019	0.0×	—

Period	P/S ratio	Change
Jun 2026	107×	(32.06%)
Mar 2026	158×	(5.87%)
Dec 2025	168×	48.40%
Sep 2025	113×	43.89%
23 more quarters	Free account

Against its own ten years

Low 0.0× High 221×

Ten-year median 37.7×

Current reading's percentile 89

Company	P/S ratio
PCVX Vaxcyte, Inc. compare	n/m
BMRN BioMarin Pharmaceutical Inc. compare	3.0×
CAI Caris Life Sciences,�Inc. compare	7.1×
TECH Bio-Techne Corp compare	9.3×
TGTX TG Therapeutics, Inc. compare	10.3×
TWST Twist Bioscience Corporation compare	17.6×
IBRX ImmunityBio, Inc. compare	51.0×
KYMR Kymera Therapeutics, Inc.	120×
SMMT Summit Therapeutics PLC compare	15,884×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Kymera Therapeutics, Inc. (KYMR) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on KYMR

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on KYMR

Stockrow Weekly